VSA 1 890812 VSA‑1 – Semisynthetic Saponin Adjuvant

For in vitro and in vivo vaccination research only.

VSA-1 is a semisynthetic saponin adjuvant derived from Momordica saponin and developed for in vitro and in vivo vaccine research. Its design supports robust humoral and cellular immune responses with improved consistency and reduced toxicity.

In BALB/c mouse studies with the PCV13 pneumococcal glycoconjugate vaccine, VSA-1 was equivalent to QS-21 in inducing IgG and opsonophagocytic titers across multiple serotypes, including 3, 14, and 19A. With lower acute toxicity and scalable production, VSA-1 is well-suited for preclinical adjuvant evaluation.